This inventor holds 1 USPTO granted patent. Top assignees: Ohara Pharmaceutical Co., Ltd., Saga University. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 5 
1 out of 62 
Years Active: 2025
Title: Innovations by Tatsuro Watanabe
Introduction
Tatsuro Watanabe is a notable inventor based in Saga, Japan. He has made significant contributions to the field of medicine, particularly in developing therapeutic agents for cancer treatment. His work focuses on addressing challenges associated with TKI-resistant chronic myeloid leukemia (CML).
Latest Patents
Watanabe holds a patent for the use of a DNMT inhibitor. This invention aims to provide a compound as a therapeutic or prophylactic agent for TKI-resistant CML, serving as a replacement for the injection “Dacogen®.” This compound demonstrates remarkable stability against cytidine deaminase and can be absorbed in vivo through oral administration. It is incorporated into the biosynthesis route of nucleic acid and effectively inhibits DNA methyltransferase (DNMT).
Career Highlights
Throughout his career, Tatsuro Watanabe has worked with esteemed organizations such as Ohara Pharmaceutical Co., Ltd. and Saga University. His experience in these institutions has contributed to his expertise in pharmaceutical research and development.
Collaborations
Watanabe has collaborated with Yuki Kurahashi, enhancing the scope and impact of his research endeavors.
Conclusion
Tatsuro Watanabe's innovative work in developing therapeutic agents for TKI-resistant CML showcases his dedication to advancing medical science. His contributions are vital in the ongoing fight against cancer, and his patent reflects a significant step forward in treatment options.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile